Greenwich LifeSciences (GLSI) vs Larimar Therapeutics (LRMR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Greenwich LifeSciences (GLSI) has outperformed Larimar Therapeutics (LRMR) over the past year, gaining 53.3% versus a loss of 52.7%. Over five years, GLSI leads with a -59.0% price change compared with -84.5% for LRMR. Greenwich LifeSciences is the larger company by market cap ($213.6 million vs $206.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GLSI | LRMR |
|---|---|---|
| Share price | $14.55 | $1.99 |
| Market cap | $213.57M | $206.21M |
| 1-day change | -5.03% | -0.25% |
| YTD return | -30.75% | -47.90% |
| 1-year return | +53.32% | -52.74% |
| 5-year return | -58.96% | -84.48% |
| EPS (TTM) | $-1.53 | $-1.99 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-19.36M | $-165.67M |
| 52-week high | $34.10 | $6.42 |
| 52-week low | $7.78 | $1.92 |
| Distance from 52-week high | -57.33% | -69.08% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +291.75% | +625.44% |
| Average volume | 140.13K | 1.31M |
| Shares outstanding | 14.68M | 103.88M |
| Employees | — | 71 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GLSI has outperformed LRMR by 106.1 percentage points over the past year.
About Greenwich LifeSciences
GLSI stock →Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States. Its lead product candidate is GP2, a HER2/neu transmembrane peptide, which is in Phase III clinical trial to prevent breast cancer recurrences in patients.
Health Care · Biotechnology: Pharmaceutical Preparations
About Larimar Therapeutics
LRMR stock →Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 71 employees
GLSI vs LRMR FAQ
Which is bigger, Greenwich LifeSciences or Larimar Therapeutics?
Greenwich LifeSciences (GLSI) is larger, with a market capitalization of $213.57M compared with $206.21M for Larimar Therapeutics (LRMR).
Which stock has performed better over the past year, GLSI or LRMR?
GLSI returned +53.32% over the past 12 months, compared with -52.74% for LRMR (price return, excluding dividends). Past performance does not predict future results.
Are Greenwich LifeSciences and Larimar Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.